Navigation Links
New Research Published Describing an Innovative Concept for Treating Widespread Fibromyalgia Pain
Date:6/30/2017

SAN DIEGO, June 30, 2017 /PRNewswire/ -- AVACEN Medical (AVACEN) announced the publication of new research in the peer-reviewed Fibromyalgia Open Access Journal. The research describes the use of its AVACEN Treatment Method to significantly reduce the widespread pain symptom experienced by those suffering from fibromyalgia.

AVACEN Medical
AVACEN Medical

Fibromyalgia is characterized by chronic widespread pain. It affects approximately 200 to 400 million people worldwide according to The National Fibromyalgia Association. It has a devastating impact on those who suffer from the disease and their personal support systems. In addition, it imposes a large economic burden on public and private healthcare providers.

The AVACEN 100 is a Class II medical device that uses the AVACEN Treatment Method. It recently received CE (Conformité Européenne) Mark approval to treat widespread pain associated with fibromyalgia.  The CE Mark allows AVACEN to market the AVACEN 100 to the European Union's 28 member countries where many prescription drugs available in the U.S. have been rejected by regulatory officials for treating fibromyalgia pain.

The AVACEN Treatment Method is an entirely new concept in chronic pain treatment that noninvasively and safely infuses heat into the circulatory system to create muscular relaxation while increasing microcirculation throughout the body. Unlike other medical devices providing local pain relief, the AVACEN 100's unique mechanism of action offers widespread pain relief.

AVACEN Medical CEO Thomas Muehlbauer described the AVACEN 100 as "the only medical device on the market today able to provide non-invasive, rapid whole-body treatment, using a single point of contact. It is the ideal drug-free and safe alternative for relief of muscle and joint pain." Muehlbauer added, "The most exciting aspect of this newly published and peer-reviewed research is that 100% positive results were recorded for the full therapeutic treatment group. Additionally, the data demonstrated a statistically significant effect on the scientifically recognized fibromyalgia diagnosis metrics."

The AVACEN 22-person fibromyalgia study was conducted under a Cooperative Research Development Agreement with the U.S. Department of Veterans Affairs at the University of California San Diego Center for Pain Medicine, Perlman Medical Center and the VA Medical Center, San Diego.

The 28-day AVACEN follow-up study produced a statistically significant reduction of over 40% in the widespread pain index and a reduction in average tender point counts from approximately 15 to 9 (11 is used for clinical assessment). Study details can be found at https://www.avacen.com/fms and are also published on the National Institutes of Health – ClinicalTrials.gov website.

About AVACEN 100 Patents

The US Patent Office has issued 3 Patents to AVACEN which include apparatus claims directed to features of the Heat Therapy apparatus manufactured by AVACEN and method claims directed to specific methods of use, referred to by the company as the AVACEN Treatment Method.  The patents also cover innovations embodied in the AVACEN 100 system, which is expected to allow multiple therapeutic uses to alleviate symptoms associated with a circulatory, neurological, lymphatic, or endocrinal dysfunction, or any combination thereof.

Patents have also been issued for China, Australia, Japan, UK, France, Germany, Spain, Sweden and Canada. Patents are pending in India and Hong Kong.

IMPORTANT NOTES: The AVACEN 100 is not for sale in the U.S. or E.U. for any non-cleared or non-approved indication mentioned in this document.

E.U. CE-Approval: A heat therapy system indicated for the temporary relief of minor muscle and joint pain and stiffness; the temporary relief of joint pain associated with arthritis, muscle spasms, minor strains and sprains; the temporary relief of widespread pain associated with fibromyalgia; muscular relaxation; and the temporary increase of microcirculation.

U.S. FDA-Clearance: A heat therapy system indicated for the temporary relief of minor muscle and joint pain and stiffness; the temporary relief of joint pain associated with arthritis; muscle spasms; minor strains and sprains; muscular relaxation; and the temporary increase of local circulation where applied. 

About AVACEN Medical

AVACEN Medical is dedicated to the innovation and design of safe, easy to use, noninvasive drug-free alternatives for the management of pain associated with numerous chronic and acute conditions including the temporary relief of minor muscle and joint pain and stiffness associated with arthritis and potentially other conditions that can cause joint pain, such as CRPS, Reynaud's, and Lyme Disease. Founded in 2009, AVACEN Medical is headquartered in San Diego. Contact: Ryan Jeffcoat at (888) 428-2236 x 711 or 166534@email4pr.com.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/new-research-published-describing-an-innovative-concept-for-treating-widespread-fibromyalgia-pain-300482545.html


'/>"/>
SOURCE AVACEN Medical
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. IDF, in partnership with Lilly, announces second phase of BRIDGES programme funding for translational research in diabetes with focus on secondary prevention
2. Therigy and EPI-Q Announce Strategic Partnership to Expand and Advance Specialty Pharmacy Outcomes Research
3. Bayer to Highlight Oncology Franchise Research at ASCO 2017
4. US Marine Corps Systems Command Awards Thornhill Research Inc. Contract for Field Anesthesia Systems
5. MarketResearch.com Announces Distribution of European Med Tech Reimbursement Consulting ABs Research
6. Three New Research Proposals Funded By Healthy Hives 2020 Initiative
7. Research and Markets - Global Biosimilar Pipeline and Market Prospects 2017-2022: Focus on Basaglar, Inflectra, Benepali, Rituximab, Trastuzumab, Adalimumab and Bevacizumab
8. Global $20 Billion Drug Delivery Technologies Market 2016-2020 - Innovation Driven by Rapidly Expanding Injectables Market and Increasing Usage of Complex Biologics - Research and Markets
9. Global $11.93 Billion Pharmacogenomics Market 2014-2017 & 2024 - Research and Markets
10. Latin America Pharmaceutical Contract Manufacturing Services Market 2014-2017 and 2025 - Research and Markets
11. Global Arthroscopy Devices Market - Analysis, Technologies and Forecasts to 2021 - Growing Use of Robotic-assisted Techniques - Research and Markets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/2/2018)... (PRWEB) , ... August 02, 2018 , ... The Team ... celebrating this major milestone with the production of a limited production commemorative vehicle: ... Edition, the Hennessey Mustang’s 5.0L supercharged V8 engine produces 808 horsepower at 7,200 rpm ...
(Date:8/1/2018)... ANGELES (PRWEB) , ... August 01, 2018 , ... To ... and two-time UFC Bantamweight Champion TJ Dillashaw have forged a partnership. Both frontrunners ... the FORBES Top 10 List of CBD Hemp Brands in the country, and sports ...
(Date:8/1/2018)... ... August 01, 2018 , ... ... PracticeWell , a Benefit Corporation in Novato, California, to offer its DoseTracer™ Junior ... Being named a benefit partner signifies cooperative efforts between Custom PC Programming, LLC ...
Breaking Medicine Technology:
(Date:8/9/2018)... ... 2018 , ... Lyme disease is one of the fastest growing epidemics to ... – a 25-fold increase since surveillance began in 1982. According to a new report ... states and the District of Columbia. Yet, Lyme and other insect borne illnesses are ...
(Date:8/9/2018)... ... 2018 , ... Thanks to the generosity of Isagenix ... and employees, the newly established Isagenix Legacy Foundation raised $2.3 million ... percent of the donations will fund grants to nonprofit organizations that further the ...
(Date:8/7/2018)... ... August 07, 2018 , ... The American Psychiatric Nurses Association ... the 2018 Board of Directors Student Scholarship . The APNA student scholarship ... nursing and develop the next generation of leaders in the profession. , ...
(Date:8/3/2018)... ... 2018 , ... Lucyd Pte Ltd, the developer of an ... its online store. The Lucyd eShop will feature the latest technologies and trends ... , The eShop will have a number of unique benefits over other eyewear ...
(Date:8/2/2018)... ... August 02, 2018 , ... The EndBrainCancer Initiative (EBCI, formerly ... brain cancer caregiver and patient clinical trials at the Pacific Neuroscience Institute and ... , At the Pacific Neuroscience Institute and John Wayne Cancer ...
Breaking Medicine News(10 mins):